BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pimurutamab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Pimurutamab\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07358585-1999@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20270728
DTEND;VALUE=DATE:20270729
SUMMARY:Pimurutamab: Phase 1/2 readout est. (NCT07358585)
DESCRIPTION:Pimurutamab\, phase 1/2.\nStudy: A Phase Ib/II Study to Evaluat
 e HLX43 Combined With HLX07 or Serplulimab in Patients With Advanced or Me
 tastatic Colorectal Cancer\nEstimated primary completion: 28 July 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/pimurutamab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07358585
URL:https://assetmemo.bio/drug/pimurutamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06857279-1999@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Pimurutamab: Phase 2 readout est. (NCT06857279)
DESCRIPTION:Pimurutamab\, phase 2.\nStudy: A Phase II Clinical Study to Eva
 luate HLX43 in Subjects With Recurrent or Metastatic Head and Neck Squamou
 s Cell Carcinoma\nEstimated primary completion: 30 December 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/pimurutamab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06857279
URL:https://assetmemo.bio/drug/pimurutamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07459751-1999@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20300115
DTEND;VALUE=DATE:20300116
SUMMARY:Pimurutamab: Phase 2/3 readout est. (NCT07459751)
DESCRIPTION:Pimurutamab\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy: A
  Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of
  HLX43 Monotherapy or HLX43 in Combination With HLX07 Versus Docetaxel in 
 Advanced or Metastatic Squamous Non-Small Cell Lung Cancer\nEstimated prim
 ary completion: 15 January 2030. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/pimurutamab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07459751
URL:https://assetmemo.bio/drug/pimurutamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07318883-1999@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20310131
DTEND;VALUE=DATE:20310201
SUMMARY:Pimurutamab: Phase 2/3 readout est. (NCT07318883)
DESCRIPTION:Pimurutamab\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy: A
  Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplul
 imab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pe
 mbrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous 
 Non-Small Cell Lung Cancer\nEstimated primary completion: January 2031. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/pimurutamab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07318883
URL:https://assetmemo.bio/drug/pimurutamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
